Scott T. Tagawa

Sep 30, 2024 | nature.com | Andrew Armstrong |Scott T. Tagawa |Anthony Serritella

AbstractUnfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer. In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC.

Sep 26, 2024 | nature.com | Anthony Serritella |Scott T. Tagawa |Andrew Armstrong

AbstractUnfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC.

Jul 12, 2024 | targetedonc.com | Scott T. Tagawa

Scott T. Tagawa, MD, MS, FACP, FASCO, professor of medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian – Weill Cornell Medical Center, discusses the potential benefits of antibody-drug conjugates (ADCs), particularly enfortumab vedotin-efjv (Padcev; EV), in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.

Jun 13, 2024 | urotoday.com | Scott T. Tagawa

Read the Full Video TranscriptZach Klaassen: Hi, my name is Zach Klaassen, I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. We're in Chicago for ASCO 2024. I'm delighted to be joined today by Dr. Scott Tagawa, GU Medical Oncologist, Weill Cornell Medical Center. Scott, thanks so much for joining us. Scott Tagawa: Thanks very much. Happy to be here.

Jun 11, 2024 | targetedonc.com | Scott T. Tagawa

Scott T. Tagawa, MD, MS, FACP, FASCO, professor of medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian – Weill Cornell Medical Center, discusses the importance of considering a drug's overall value beyond just its initial price per mg. Tagawa recently joined Targeted OncologyTM in an interview to discuss the landscape of antibody-drug conjugates (ADCs) for the treatment of bladder cancer.